imatinib

ABL proto-oncogene 1, non-receptor tyrosine kinase ; Homo sapiens







7 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 31650445 Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells. 2020 Aug 2
2 31699386 New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia. 2020 Jan 1
3 31925328 A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein. 2020 Jan 9 1
4 31955347 Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line. 2020 Mar 1
5 31998490 An Imatinib-non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. 2020 Jan 1
6 31699612 Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants. 2019 Dec 15 4
7 31915450 Systemic Pharmacological Approach to Identification and Experimental Verification of the Effect of Anisi Stellati Fructus Extract on Chronic Myeloid Leukemia Cells. 2019 1